Albany College of Pharmacy and Health Sciences
and The Endocrine Group researchers have concluded that the OmniPod®
Insulin Management System significantly improved blood glucose control in
diabetes patients who previously received insulin through multiple daily
injections. The retrospective study results were published in the latest
issue of Infusystems USA, in a study titled, 'Clinical Experience with a
Tubing-Free Insulin Pump System.'
Lead investigator, Michael P. Kane, Pharm.D., FCCP, BCPS, Professor of
Pharmacy Practice at Albany College of Pharmacy and Health Sciences,
reported that study results showed that after one year using the OmniPod
System, patients who previously received insulin through multiple daily
injections decreased their average A1C levels by 0.49%, a statistically
significant difference. A1C levels, also known as HbA1C or glycated
hemoglobin levels, measure a patient's average blood glucose control over a
sustained period. The study also demonstrated that 25.5% of patients using
the OmniPod System reduced their A1C below 7%, compared to 5.7% of patients
prior to use of the OmniPod System. The American Diabetes Association
recommends most patients keep their A1C levels below 7%.
"This study demonstrates the benefits of a tubing-free insulin pump, which
can help patients overcome their fear of insertion sets or unsightly tubing
and achieve the clinical benefits of insulin pump therapy," said study
investigator Jill M. Abelseth, M.D., FACE of The Endocrine Group. "The high
patient acceptance, improved glycemic control and overall safety
demonstrated in this study support the use of the OmniPod System for
diabetes patients aiming for improved glycemic control."